A
Aera Therapeutics
Aera is developing a new class of genetic medicines based on its proprietary crispr-based platform
About Aera Therapeutics
Aera Therapeutics is a pioneering genetic medicines company focused on developing transformative treatments for a wide range of human diseases. The company leverages its proprietary protein nanoparticle (PNP) delivery platform, which utilizes endogenous human proteins that self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. This innovative approach aims to harness the power of genetic medicines to address unmet medical needs across various therapeutic applications.
Read full description
Aera serves a diverse clientele, including patients, healthcare providers, and pharmaceutical partners. Operating in the biotechnology and pharmaceutical markets, the company employs a business model centered around research and development (R&D), clinical trials, and strategic partnerships. Revenue is generated through the development and commercialization of genetic medicine therapies, as well as potential collaborations and licensing agreements with other biotech and pharmaceutical companies.
Under the leadership of CEO Akin Akinc, Ph.D., who brings extensive experience from his tenure at Alnylam Pharmaceuticals, Aera is well-positioned to advance its mission of delivering innovative genetic treatments. The company offers a competitive benefits package to attract top talent and foster a supportive work environment.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 88
- Open positions
- 5
- Dealroom signal
- 45.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2023 | $58M | $232M | GV · Lux Capital · ARCH Venture Partners | ↗ |
| SERIES BOther financing | Jan 2023 | $135M | $540M | Lux Capital · GV · ARCH Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Aera Therapeutics is 3.7K monthly website visits, up 15.6% over the last three months. Aera Therapeutics's team grew 7.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Other known investors2 additional known investors
Broad Institute
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.